PranaX appoints new CEO to drive exosome expansion
PranaX, a Houston, USA-based biotech specializing in exosome-based regenerative therapies, has appointed Phillip Maderia as its new chief executive as it seeks to expand its pipeline and establish a stronger foothold in the biopharmaceutical market.
Mr Maderia, who previously led the exosome manufacturing business at Swiss contract development and manufacturing organization Lonza (SIX: LONN), brings over 30 years of experience in biopharmaceutical manufacturing.
At Lonza, he oversaw the construction of the company’s first large-scale GMP exosome manufacturing facility and managed a $12 million operation. His tenure also included securing the intellectual property of Codiak BioSciences, a pioneer in exosome therapeutics that faced financial challenges despite its early leadership in the field.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze